<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Lat Am Enfermagem</journal-id><journal-id journal-id-type="iso-abbrev">Rev Lat Am Enfermagem</journal-id><journal-title-group><journal-title>Revista Latino-Americana de Enfermagem</journal-title></journal-title-group><issn pub-type="ppub">0104-1169</issn><issn pub-type="epub">1518-8345</issn><publisher><publisher-name>Escola de Enfermagem de Ribeir&#x000e3;o Preto / Universidade de S&#x000e3;o
Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25806626</article-id><article-id pub-id-type="pmc">4376026</article-id><article-id pub-id-type="doi">10.1590/0104-1169.0144.2519</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Quality of life of coronary artery disease patients after the
implementation of planning strategies for medication adherence<xref ref-type="fn" rid="fn01">
<sup>1</sup>
</xref>
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>Laura Bacelar de Araujo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Roberta Cunha Matheus</given-names></name><xref ref-type="aff" rid="aff2">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e3;o-Jo&#x000e3;o</surname><given-names>Tha&#x000ed;s Moreira</given-names></name><xref ref-type="aff" rid="aff3">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gallani</surname><given-names>Maria Cecilia</given-names></name><xref ref-type="aff" rid="aff4">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Corn&#x000e9;lio</surname><given-names>Marilia Estevam</given-names></name><xref ref-type="aff" rid="aff5">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>2</label>RN, MSc, Hospital do Cora&#x000e7;&#x000e3;o de Campinas, Campinas, SP,
<country>Brazil</country></aff><aff id="aff2"><label>3</label>PhD, Associate Professor, Faculdade de Enfermagem, Universidade Estadual
de Campinas, Campinas, SP, <country>Brazil</country></aff><aff id="aff3"><label>4</label>Post-doctoral fellow, Faculdade de Enfermagem, Universidade Estadual de
Campinas, Campinas, SP, <country>Brazil</country></aff><aff id="aff4"><label>5</label>PhD, Full Professor, Facult&#x000e9; des sciences infirmi&#x000e8;res, Universit&#x000e9; Laval,
Qu&#x000e9;bec, <country>Canada</country></aff><aff id="aff5"><label>6</label>PhD, Associate Professor, Universidade Federal de S&#x000e3;o Carlos, S&#x000e3;o
Carlos, SP, <country>Brasil</country></aff><author-notes><corresp id="c01"><bold>Corresponding Author:</bold> Roberta Cunha Matheus Rodrigues Universidade
Estadual de Campinas. Faculdade de Enfermagem Rua Tess&#x000e1;lia Vieira de Camargo, 126
Cidade Universit&#x000e1;ria "Zeferino Vaz" CEP: 13083-887, Campinas, SP, Brasil E-mail:
<email>rroberta@unicamp.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>23</volume><issue>1</issue><fpage>11</fpage><lpage>19</lpage><history><date date-type="received"><day>15</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>OBJECTIVE:</title><p> to compare the general and specific health-related quality of life (HRQoL)
between the Intervention (IG) and Control (CG) groups of coronary artery disease
patients after the implementation of Action Planning and Coping Planning
strategies for medication adherence and to verify the relationship between
adherence and HRQoL. </p></sec><sec><title>METHOD:</title><p> this was a controlled and randomized study. </p></sec><sec><title>RESULTS:</title><p> the sample (n=115) was randomized into two groups, IG (n=59) and CG (n=56).
Measures of medication adherence and general and specific HRQoL were obtained in
the baseline and after two months of monitoring. </p></sec><sec><title>CONCLUSION:</title><p> the findings showed that the combination of intervention strategies - Action
Planning and Coping Planning for medication adherence did not affect the HRQoL of
coronary artery disease patients in outpatient monitoring.</p></sec></abstract><kwd-group><kwd>Nursing</kwd><kwd>Medication Adherence</kwd><kwd>Health Behavior</kwd><kwd>Planning Techniques</kwd><kwd>Coronary Disease</kwd></kwd-group><counts><fig-count count="0"/><table-count count="6"/><equation-count count="0"/><ref-count count="25"/><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Patient adherence to medication therapy is essential for the control of coronary artery
disease (CAD) and prevention of its complications<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>, constituting one of the biggest challenges for the nursing care to
coronary disease patients, given the high percentage of non-adherence to the therapeutic
medication regimen<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup>. This construct refers to the extent to which patients follow the
instructions of their physician or other healthcare professionals<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>. It is a complex phenomenon influenced by a range of factors, including,
individual beliefs, skills, financial resources and/or barriers, and social
influences<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>. Among the causes of non-adherence, the need for continued treatment can be
highlighted, as well as the perceived lack of immediate benefits, the potential for
adverse effects, and the costs associated with the treatment<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>.</p><p>Medication adherence can have significant impact on the health-related quality of life
(HRQoL) in patients with chronic clinical conditions<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>-</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup>, including CAD<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>. Although they are different constructs, adherence and HRQoL are related to
patients and should be considered when evaluating the impact of interventions that
affect their health<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup>
<sub>.</sub> Furthermore, these constructs are considered distinct outcomes in the care
process - while adherence constitutes an intermediate result, HRQoL can be understood as
a final outcome of the treatment<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup>. Thus, it is possible to assume that interventions outlined for optimizing
adherence influence medication adherence <italic>a priori</italic> and subsequently the
HRQoL.</p><p>Although targeted at different health conditions, some studies have investigated the
relationship between HRQoL and adherence. Among these, cross-sectional studies with
geriatric hypertensive patients<sup>(</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup>, the use of medication for treatment of acquired immunodeficiency
syndrome<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup> and treatment with lipid-lowering drugs<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> can be highlighted. A recent literature review showed that few longitudinal
studies have evaluated the impact of a theory-based intervention for the promotion or
optimization of medication adherence on the general and specific HRQoL of patients with
chronic<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup> clinical conditions, especially among CAD patients.</p><p>Considering the importance of medication adherence and HRQoL in CAD secondary prevention
programs, this study aimed to compare the general and specific HRQoL measures of
coronary artery disease patients randomized into the intervention group (IG) and control
group (CG) before and after the implementation of Action Planning and Coping Planning
strategies for medication adherence, and to verify the relationship between medication
adherence and general and specific HRQoL throughout the monitoring.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects and Procedures</title><p>Data from this study are derived from a broader experimental study<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup> that evaluated the effect of planning strategies on medication adherence
and HRQoL of coronary artery disease patients. The sample consisted of CAD patients
aged over 18, with prior clinical manifestation of angina or myocardial infarction
(MI), with more than six months since the last ischemic event, and undergoing
outpatient monitoring at one of the two hospitals in the state of S&#x000e3;o Paulo. Those
who demonstrated an ability to communicate verbally and had been continuously using
at least two oral drugs for CAD treatment (cardio protective and symptom relief
medications) for at least a month were included. Those whose pharmacological
treatment has been suspended or modified at the time of the initial approach
(T<sub>0</sub>) were excluded. The participation of those patients who did not
attend the scheduled follow-up appointments at one (T<sub>1</sub>) and two months
(T<sub>2</sub>) after the baseline was discontinued, as well as those whose
pharmacological therapy was suspended or modified during the monitoring period.</p></sec><sec><title>Sample</title><p>After the acceptance of the invitation to participate in the study and provision of
the formal consent by signing the Terms of Informed Consent, the subjects were
randomized into control group (CG) or intervention group (IG). The aleatorization was
based on a random sequence list generated by the SAS, version 9.1.3 program (SAS
Institute Inc., Cary NC, USA, 2002-2003). The patients of the IG were submitted to
the planning strategies - Action Planning and Coping Planning, applied by the main
researcher; while the patients in the CG received usual care.</p></sec><sec><title>Data Collection</title><p>Data were gathered from June 2010 to May 2011, using structured interviews and
consultation of the hospital medical records at two different times:</p><p>- T<sub>0</sub> (baseline): interview and consent of the patient to participate in
the study obtained by signing the term. Data related to sociodemographic and clinical
characterization, medication adherence<sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>, factors related to non-adherence<sup>(</sup>
<xref rid="B13" ref-type="bibr">13</xref>
<sup>)</sup> and general and specific<sup>(</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>)</sup> HRQoL<sup>(</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup> were obtained;</p><p>- T<sub>2 </sub>(two months after T<sub>0</sub>): adherence and HRQoL measures were
again obtained.</p></sec><sec><title>Intervention</title><p>The intervention was applied at T<sub>0</sub> with only those patients in the IG and
consisted of the formulation and implementation of plans, according to the
theoretical assumptions of Implementation Intention<sup>(</sup>
<xref rid="B16" ref-type="bibr">16</xref>
<sup>-</sup>
<xref rid="B17" ref-type="bibr">17</xref>
<sup>)</sup>, based on a previous Brazilian study<sup>(</sup>
<xref rid="B18" ref-type="bibr">18</xref>
<sup>)</sup>. Patients were asked to design, in conjunction with the researcher,
action and coping plans related to medication adherence. At T<sub>1</sub> (one month
after T<sub>0</sub>) presential reinforcement of the planning strategies was
performed, by reading together the plans prepared at T<sub>0.</sub> The details of
the intervention can be found in a previous study<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup>.</p></sec><sec><title>Control</title><p>The patients allocated to the CG received the routine care of the unit, which
consisted of the usual clinical monitoring performed at the outpatient clinic. They
were instructed to maintain their routine activities as well as their clinical
follow-up appointments with the physician.</p></sec><sec><title>Instruments</title><p>
<italic>- </italic>The Morisky Self-Reported Measure of Medication Adherence
Scale<sup>(</sup>
<xref rid="B13" ref-type="bibr">13</xref>
<sup>)</sup>: composed of four questions relating to non-adherence to pharmacological
treatment, structured in Likert-type scales with four or five answer choices, the sum
of which generates a score ranging from 4 up to 18; the lower the score the higher
the favorability to adherence.</p><p>
<italic>- </italic>Proportion of medication adherence (<italic>Propor&#x000e7;&#x000e3;o de ades&#x000e3;o
medicamentosa</italic>)<sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>: constructed to identify and quantify medications and their form of use.
It includes the following variables: Name, strength and dosage of the prescribed
medications; Description of the form of use of each medication, according to the
strength and dosage, in the previous 24 hours; in the previous week, and in the month
prior to the interview. Adherence was calculated based on self-reported missed doses,
using the calculation: [(Prescribed doses - missed doses) x 100 / prescribed
doses]<sup>(</sup>
<xref rid="B19" ref-type="bibr">19</xref>
<sup>)</sup>. Those who obtained a percentage of consumption of prescribed
medications, equal to or greater than 80%<sup>(20) </sup>were considered "Adherent".
For those who used more than one medication, the proportion of adherence was
calculated through the mean of the percentages of adherence to each
medication<sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>. The proportion of adherence was analyzed as a continuous and binary
variable - <italic>appropriate dose</italic> (dose used &#x02265;80% of the prescribed dose)
and <italic>inappropriate dose</italic> (dose &#x0003c;80% of the prescribed dose).</p><p>
<italic>- </italic>Overall adherence assessment: the number and frequency of
medications taken were evaluated, as well as their association with temporal markers:
fasting, breakfast, lunch and dinner. This was evaluated based on the following
classification: Group I (appropriate dosage and care for the prescription); Group II
(appropriate dosage and inappropriate care), Group III (inappropriate dosage and
appropriate care) and Group IV (inappropriate dosage and care). The patients
classified in group I were considered "Adherent", and those classified in groups II,
III, and IV "Non-adherent" <sup>(</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>. </p><p>
<italic>- </italic>The MacNew Heart Disease Health-related Quality of Life
Questionnaire (MacNew): consists of a modified version of the "Quality of Life after
Myocardial Infarction" (QLMI) original<sup>(</sup>
<xref rid="B21" ref-type="bibr">21</xref>
<sup>)</sup> instrument and is composed of the domains: Physical Functioning (13
items), Emotional Functioning (14 items) and Social Functioning (13 items). An item
can be part of more than one domain. The maximum possible score in any domain is
seven (indicating the best HRQoL) and the minimum is one (suggesting the worst
HRQoL). Items not answered do not contribute to the score and item 27 (sexual
relations) can be excluded without affecting the final score of the domain. Domain
scores are calculated through the arithmetic mean of the responses of that domain. If
more than 50% of the items of a domain are not answered, the score for that domain is
not calculated. The total score is calculated through the arithmetic mean of all the
items answered, unless one of the domains is completely missing<sup>(</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>)</sup>. The Brazilian version of MacNew<sup>(</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>)</sup> is considered reliable, valid and simple to apply<sup>(</sup>
<xref rid="B15" ref-type="bibr">15</xref>
<sup>,</sup>
<xref rid="B23" ref-type="bibr">23</xref>
<sup>)</sup>. In the present study the reliability with respect to the internal
consistency, assessed through </p><p>Cronbach's alpha coefficient, ranged between 0.80 and 0.90 throughout the
monitoring.</p><p>
<italic>- </italic>The 36-item Short Form Health Survey - SF-36: is a generic
evaluation instrument of the perceived health status<sup>(</sup>
<xref rid="B24" ref-type="bibr">24</xref>
<sup>)</sup>, which is easy to administer and comprehend. It consists of eight
domains: Functional Capacity (ten items), Physical Aspects (four items), Pain (two
items), General Health Status (five items), Vitality (four items), Social Aspects
(two items), Emotional Aspects (three items), Mental Health (five items), and one
question comparing the current health conditions with those of one year previous. The
final score ranges from zero (worst health status) up to 100 (best health
status)<sup>(</sup>
<xref rid="B24" ref-type="bibr">24</xref>
<sup>)</sup>
<sub>.</sub> The Brazilian version of the SF-36<sup>(</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup> was used and, in the present study, the internal consistency, assessed
through Cronbach's alpha coefficient, ranged between 0.80 and 0.90 throughout the
monitoring.</p></sec><sec><title>Data Analysis</title><p>Descriptive analyzes were performed to characterize the sample according to
sociodemographic, clinical, medication adherence, and HRQoL variables. Student's
t-test was used to check for differences between sociodemographic and clinical
variables and the general and specific HRQoL between the IG and CG groups at
T<sub>0</sub>. The paired Student's t-test was used to check for differences in
the HRQoL means between the pre- (T<sub>0</sub>) and post-intervention
(T<sub>2</sub>) times. Simple linear regression analyzes were used to evaluate change
in the HRQoL at T<sub>2</sub>. Pearson's correlation coefficient was used to verify
the relationship between medication adherence and HRQoL. Correlation coefficients
&#x0003c; 0.30 were considered of weak magnitude, between 0.30 and 0.50 as moderate and
&#x0003e; 0.50 of strong magnitude<sup>(</sup>
<xref rid="B25" ref-type="bibr">25</xref>
<sup>)</sup>. The significance level adopted for the statistical tests was p &#x02264;
0.05.</p></sec><sec><title>Ethical Aspects</title><p>The study was approved by the Research Ethics Committee of a university in the state
of S&#x000e3;o Paulo (Document No. 802/2009) and the Research Ethics Committee of a municipal
hospital in the state of S&#x000e3;o Paulo (Document No. 001-11), as determined by Resolution
No. 196/96 of the National Health Council/Ministry of Health. Patients were invited
to participate in the study through the explanation and careful reading of the
consent form, being informed about the aims of the study and data collection
procedure, as well as the voluntary nature of their participation, their guaranteed
anonymity and freedom to withdraw at any time without any loss regarding healthcare.
</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Sociodemographic and clinical Characterization</title><p>At T<sub>0</sub>, 134 patients were considered eligible for the study. Of these, 8
were excluded due to the presence of at least one exclusion criterion. Thus, the
sample consisted of 126 patients, of whom 62 were allocated to the CG and 64 to the
IG. After the first approach, 5 patients were excluded from the CG and 6 from the IG
due to non-attendance of the scheduled appointments. Thus, 115 patients completed the
study (CG= 56; IG= 59). The comparative analysis between the groups at T<sub>0</sub>
showed that there were no differences between the groups regarding the
sociodemographic and clinical variables, except for the number of previous myocardial
infarctions, which was significantly higher in the IG (p=0.02).</p><p>The majority of the subjects consumed a mean of 6.4 (2.0) types of medication, with a
mean of 3.6 (0.6) cardioprotective medications, and 0.8 (0.7) symptom relief
medications. When using the proportion of adherence and the Morisky adherence scale,
it was observed that the group was characterized by non-adherence. When considering
the proportion of adherence in association with appropriate care, the majority was
classified as non-adherent. However, in the IG there was a significant percentage of
individuals that were adherent, when using the overall evaluation of adherence
measure (p=0.023) (<xref ref-type="table" rid="t01">Table 1</xref>).</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1 -</label><caption><title>Sociodemographic and clinical characterization of the Total 115 patients
with Coronary Artery Disease and of the patients in the Intervention Group
(n=59) and Control Group (n=56) in the baseline (T0). Campinas, SP, Brazil,
2010-2011</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th colspan="3" rowspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Total Group<break/>
(n=115)</th><th align="center" rowspan="1" colspan="1">Intervention Group<break/>
(N=59)</th><th align="center" rowspan="1" colspan="1">Control Group<break/>
(N=56)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"> Sociodemographic</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Age, Mean (SD*)</td><td align="center" rowspan="1" colspan="1"> 62.0 (9.0)</td><td align="center" rowspan="1" colspan="1"> 63.4 (8.9)</td><td align="center" rowspan="1" colspan="1"> 60.6 (9.0)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Gender, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Male</td><td align="center" rowspan="1" colspan="1"> 75 (65.2)</td><td align="center" rowspan="1" colspan="1"> 40 (67.8)</td><td align="center" rowspan="1" colspan="1"> 35 (62.5)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Marital Arrangement, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> With partner</td><td align="center" rowspan="1" colspan="1"> 83 (72.2)</td><td align="center" rowspan="1" colspan="1"> 44 (74.6)</td><td align="center" rowspan="1" colspan="1"> 39 (69.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Education (years), Mean (SD*)</td><td align="center" rowspan="1" colspan="1"> 5.8 (4.1)</td><td align="center" rowspan="1" colspan="1"> 5.5 (4.0)</td><td align="center" rowspan="1" colspan="1"> 6.2 (4.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Habits/Lifestyle, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Current smoker (yes)</td><td align="center" rowspan="1" colspan="1"> 13 (11.3)</td><td align="center" rowspan="1" colspan="1"> 3 (5.1)</td><td align="center" rowspan="1" colspan="1"> 10 (17.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Employment Situation, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Unemployed</td><td align="center" rowspan="1" colspan="1"> 71 (61.7)</td><td align="center" rowspan="1" colspan="1"> 44 (74.6)</td><td align="center" rowspan="1" colspan="1"> 33 (58.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Employed</td><td align="center" rowspan="1" colspan="1"> 31 (26.9)</td><td align="center" rowspan="1" colspan="1"> 9 (15.2)</td><td align="center" rowspan="1" colspan="1"> 22 (39.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Housewife/husband</td><td align="center" rowspan="1" colspan="1"> 10 (8.7)</td><td align="center" rowspan="1" colspan="1"> 5 (8.5)</td><td align="center" rowspan="1" colspan="1"> 5 (8.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Family income (MW<sup>&#x02020;</sup>), Mean
(SD*)</td><td align="center" rowspan="1" colspan="1"> 3.0 (3.6)</td><td align="center" rowspan="1" colspan="1"> 3.2 (3.6)</td><td align="center" rowspan="1" colspan="1"> 2.7 (3.5)</td></tr><tr><td colspan="6" rowspan="1"> Clinical</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Characterization of coronary disease, n
(%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Unstable Angina</td><td align="center" rowspan="1" colspan="1"> 24 (20.9)</td><td align="center" rowspan="1" colspan="1"> 15 (25.4)</td><td align="center" rowspan="1" colspan="1"> 9 (16.1)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Myocardial infarction</td><td align="center" rowspan="1" colspan="1"> 91 (79.1)</td><td align="center" rowspan="1" colspan="1"> 44 (74.5)</td><td align="center" rowspan="1" colspan="1"> 47 (83.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Number of previous infarctions, Mean
(SD*)</td><td align="center" rowspan="1" colspan="1"> 0.7 (1.1)</td><td align="center" rowspan="1" colspan="1"> 1.0 (1.3)<sup>&#x02021;</sup>
</td><td align="center" rowspan="1" colspan="1"> 0.5 (0.9)<sup>&#x02021;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Symptoms (in the previous
month)<sup>&#x000a7;</sup>, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Precordialgia</td><td align="center" rowspan="1" colspan="1"> 51 (44.3)</td><td align="center" rowspan="1" colspan="1"> 31 (52.5)</td><td align="center" rowspan="1" colspan="1"> 20 (35.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Dyspnoea</td><td align="center" rowspan="1" colspan="1"> 48 (41.7)</td><td align="center" rowspan="1" colspan="1"> 24 (40.7)</td><td align="center" rowspan="1" colspan="1"> 24 (42.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Lower limb edema</td><td align="center" rowspan="1" colspan="1"> 40 (34.8)</td><td align="center" rowspan="1" colspan="1"> 23 (39.0)</td><td align="center" rowspan="1" colspan="1"> 17 (30.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Palpitations</td><td align="center" rowspan="1" colspan="1"> 32 (27.8)</td><td align="center" rowspan="1" colspan="1"> 18 (30.5)</td><td align="center" rowspan="1" colspan="1"> 14 (25.0)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Lipothymy</td><td align="center" rowspan="1" colspan="1"> 27 (23.5)</td><td align="center" rowspan="1" colspan="1"> 16 (27.1)</td><td align="center" rowspan="1" colspan="1"> 11 (19.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Number of Associated Clinical Conditions,
Mean (SD*)</td><td align="center" rowspan="1" colspan="1"> 5.0 (1.8)</td><td align="center" rowspan="1" colspan="1"> 5.1 (1.9)</td><td align="center" rowspan="1" colspan="1"> 4.8 (1.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Associated Clinical Conditions<sup>&#x000a7;</sup>,
n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Dyslipidemia</td><td align="center" rowspan="1" colspan="1"> 91 (79.1)</td><td align="center" rowspan="1" colspan="1"> 51 (86.4)</td><td align="center" rowspan="1" colspan="1"> 40 (71.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Arterial Hypertension</td><td align="center" rowspan="1" colspan="1"> 88 (76.5)</td><td align="center" rowspan="1" colspan="1"> 50 (84.7)</td><td align="center" rowspan="1" colspan="1"> 38 (67.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Diabetes mellitus</td><td align="center" rowspan="1" colspan="1"> 41 (35.6)</td><td align="center" rowspan="1" colspan="1"> 27 (45.8)</td><td align="center" rowspan="1" colspan="1"> 14 (25.0)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Treatment, n (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Clinical and Intervention
(MR<sup>||</sup>/MRA<sup>&#x000b6;</sup>/MR<sup>||</sup> and
MRA<sup>&#x000b6;</sup>)</td><td align="center" rowspan="1" colspan="1"> 84 (73.0)</td><td align="center" rowspan="1" colspan="1"> 40 (67.4)</td><td align="center" rowspan="1" colspan="1"> 44 (78.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Clinical</td><td align="center" rowspan="1" colspan="1"> 31 (27.0)</td><td align="center" rowspan="1" colspan="1"> 19 (32.2)</td><td align="center" rowspan="1" colspan="1"> 12 (21.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Number of medications in use, Mean
(SD*)</td><td align="center" rowspan="1" colspan="1"> 6.4 (2.0)</td><td align="center" rowspan="1" colspan="1"> 6.8 (2.0)</td><td align="center" rowspan="1" colspan="1"> 5.9 (1.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Number of Cardioprotective Medications, Mean
(SD*)</td><td align="center" rowspan="1" colspan="1"> 3.6 (0.6)</td><td align="center" rowspan="1" colspan="1"> 3.5 (0.6)</td><td align="center" rowspan="1" colspan="1"> 3.7 (0.5)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Number of Symptom Relief Medications, Mean
(SD*)</td><td align="center" rowspan="1" colspan="1"> 0.8 (0.7)</td><td align="center" rowspan="1" colspan="1"> 0.9 (0.7)</td><td align="center" rowspan="1" colspan="1"> 0.8(0.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Total Morisky score, Mean (SD*)</td><td align="center" rowspan="1" colspan="1"> 6.9 (2.8)</td><td align="center" rowspan="1" colspan="1"> 7.3 (3.1)</td><td align="center" rowspan="1" colspan="1"> 6.5 (2.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Proportion of Adherence, Mean (SD*)</td><td align="center" rowspan="1" colspan="1"> 92.9 (12.1)</td><td align="center" rowspan="1" colspan="1"> 92.1 (13.7)</td><td align="center" rowspan="1" colspan="1"> 93.7 (10.2)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Proportion of Adherence<sup>&#x000a7;</sup>, n
(%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Appropriate dose (&#x02265;80%)</td><td align="center" rowspan="1" colspan="1"> 53 (89.8)</td><td align="center" rowspan="1" colspan="1"> 52 (88.1)</td><td align="center" rowspan="1" colspan="1"> 50 (89.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Inappropriate dose
(&#x0003c;80%)</td><td align="center" rowspan="1" colspan="1"> 6 (10.2)</td><td align="center" rowspan="1" colspan="1"> 7 (11.9)</td><td align="center" rowspan="1" colspan="1"> 6 (10.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td colspan="2" rowspan="1"> Overall adherence assessment<sup>&#x000a7;</sup>, n
(%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Adherent</td><td align="center" rowspan="1" colspan="1"> 27 (23.5)</td><td align="center" rowspan="1" colspan="1"> 19 (32.2)</td><td align="center" rowspan="1" colspan="1"> 8 (14.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Non-Adherent</td><td align="center" rowspan="1" colspan="1"> 88 (76.5)</td><td align="center" rowspan="1" colspan="1"> 40 (67.8)</td><td align="center" rowspan="1" colspan="1"> 48 (85.7)</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>*</label><p>Standard Deviation</p></fn><fn id="TFN02"><label>&#x02020;</label><p>Minimum wage (R$ 545.00)</p></fn><fn id="TFN03"><label>&#x02021;</label><p>Student's t test, p=0.02 &#x000a7;Percentage per line</p></fn><fn id="TFN04"><label>||</label><p>Surgical Myocardial Revascularization</p></fn><fn id="TFN05"><label>&#x000b6;</label><p> Myocardial Revascularization by Angioplasty</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Analysis of Health Related Quality of Life (HRQoL) measures</title><p>Regarding the specific HRQoL (MacNew), significantly higher mean scores (p&#x0003c;0.05)
for all domains of the MacNew were observed in the IG at T<sub>2</sub>, when compared
to the baseline (T<sub>0</sub>). However, a significant increase in the scores of the
majority of the MacNew domains was also observed in the CG, except in the emotional
functioning domain, however, these differences were not statistically significant
(<xref ref-type="table" rid="t02">Table 2</xref>). Regarding the generic HRQoL,
significantly higher scores at T<sub>2</sub> were observed in the IG in the
Functional Capacity (p&#x0003c;0.001) and Emotional Aspects (p&#x0003c;0.05) domains, when
compared to the scores obtained at T<sub>0</sub>. In the CG no significant
differences were observed between the scores obtained at T<sub>2</sub> and
T<sub>0</sub>.</p><p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2 -</label><caption><title>Descriptive analysis of the scores of general (SF-36) and specific
(MacNew) Health Related Quality of Life of coronary disease patients
distributed into intervention group (n=59) and control group (n=62), at T0
and T2. Campinas, SP, Brazil, 2010-2011</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th colspan="2" rowspan="3">
</th><th colspan="3" rowspan="1">Intervention Group (n=59)</th><th align="center" rowspan="1" colspan="1">
</th><th colspan="3" rowspan="1">Control Group (n=56)</th></tr><tr><th align="center" rowspan="1" colspan="1">T<sub>0</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>2</sub>
</th><th rowspan="2" colspan="1">Mean differences
(T<sub>2</sub>-T<sub>0</sub>)</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">T<sub>0</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>2</sub>
</th><th rowspan="2" colspan="1">Mean differences
(T<sub>2</sub>-T<sub>0</sub>)</th></tr><tr><th align="center" rowspan="1" colspan="1">Mean (SD*)</th><th align="center" rowspan="1" colspan="1">Mean (SD*)</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Mean (SD*)</th><th align="center" rowspan="1" colspan="1">Mean (SD*)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"> MacNew</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Physical Functioning</td><td align="center" rowspan="1" colspan="1"> 4.8 (1.2)</td><td align="center" rowspan="1" colspan="1"> 5.2 (1.1)</td><td align="center" rowspan="1" colspan="1"> 0.4<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5.0 (1.3)</td><td align="center" rowspan="1" colspan="1"> 5.3 (1.1)</td><td align="center" rowspan="1" colspan="1"> 0.3<sup>&#x02021;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Emotional Functioning</td><td align="center" rowspan="1" colspan="1"> 4.9 (1.1)</td><td align="center" rowspan="1" colspan="1"> 5.2 (0.9)</td><td align="center" rowspan="1" colspan="1"> 0.3<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5.2 (1.3)</td><td align="center" rowspan="1" colspan="1"> 5.4 (1.1)</td><td align="center" rowspan="1" colspan="1"> 0.2</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Social Functioning</td><td align="center" rowspan="1" colspan="1"> 4.7 (1.2)</td><td align="center" rowspan="1" colspan="1"> 5.1 (1.1)</td><td align="center" rowspan="1" colspan="1"> 0.4<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5.0 (1.2)</td><td align="center" rowspan="1" colspan="1"> 5.3 (1.1)</td><td align="center" rowspan="1" colspan="1"> 0.3<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Total</td><td align="center" rowspan="1" colspan="1"> 4.8 (1.0)</td><td align="center" rowspan="1" colspan="1"> 5.1 (0.9)</td><td align="center" rowspan="1" colspan="1"> 0.3<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5.0 (1.1)</td><td align="center" rowspan="1" colspan="1"> 5.3 (1.0)</td><td align="center" rowspan="1" colspan="1"> 0.3<sup>&#x02020;</sup>
</td></tr><tr><td colspan="2" rowspan="1"> SF-36</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Functional Capacity</td><td align="center" rowspan="1" colspan="1"> 49.1 (22.3)</td><td align="center" rowspan="1" colspan="1"> 54.4 (28.7)</td><td align="center" rowspan="1" colspan="1"> 5.3<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 55.4 (28.4)</td><td align="center" rowspan="1" colspan="1"> 58.4 (27.8)</td><td align="center" rowspan="1" colspan="1"> 3.0</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Physical Aspects</td><td align="center" rowspan="1" colspan="1"> 39.0 (29.1)</td><td align="center" rowspan="1" colspan="1"> 36.9 (38.1)</td><td align="center" rowspan="1" colspan="1"> -2.1</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 43.7 (40.5)</td><td align="center" rowspan="1" colspan="1"> 44.2 (39.3)</td><td align="center" rowspan="1" colspan="1"> 0.5</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Pain</td><td align="center" rowspan="1" colspan="1"> 55.8 (24.3)</td><td align="center" rowspan="1" colspan="1"> 61.2 (25.7)</td><td align="center" rowspan="1" colspan="1"> 5.4</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 56.5 (28.0)</td><td align="center" rowspan="1" colspan="1"> 58.5 (27.2)</td><td align="center" rowspan="1" colspan="1"> 2.0</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> General Health Status</td><td align="center" rowspan="1" colspan="1"> 59.0 (20.6)</td><td align="center" rowspan="1" colspan="1"> 61.1 (17.4)</td><td align="center" rowspan="1" colspan="1"> 2.1</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 60.2 (21.6)</td><td align="center" rowspan="1" colspan="1"> 57.4 (18.7)</td><td align="center" rowspan="1" colspan="1"> -2.8</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Vitality</td><td align="center" rowspan="1" colspan="1"> 56.2 (23.2)</td><td align="center" rowspan="1" colspan="1"> 56.3 (21.1)</td><td align="center" rowspan="1" colspan="1"> 0.1</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 56.4 (22.9)</td><td align="center" rowspan="1" colspan="1"> 54.3 (21.9)</td><td align="center" rowspan="1" colspan="1"> -2.1</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Social Aspects</td><td align="center" rowspan="1" colspan="1"> 60.4 (28.0)</td><td align="center" rowspan="1" colspan="1"> 70.8 (25.9)</td><td align="center" rowspan="1" colspan="1"> 10.4<sup>&#x02020;</sup>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 64.3 (29.6)</td><td align="center" rowspan="1" colspan="1"> 69.4 (26.6)</td><td align="center" rowspan="1" colspan="1"> 5.1</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Emotional Aspects</td><td align="center" rowspan="1" colspan="1"> 42.4 (39.1)</td><td align="center" rowspan="1" colspan="1"> 51.4 (41.2)</td><td align="center" rowspan="1" colspan="1"> 9.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 49.4 (41.2)</td><td align="center" rowspan="1" colspan="1"> 55.9 (38.2)</td><td align="center" rowspan="1" colspan="1"> 6.5</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Mental Health</td><td align="center" rowspan="1" colspan="1"> 61.4 (22.3)</td><td align="center" rowspan="1" colspan="1"> 62.4 (19.6)</td><td align="center" rowspan="1" colspan="1"> 1.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 63.1 (22.2)</td><td align="center" rowspan="1" colspan="1"> 62.6 (21.0)</td><td align="center" rowspan="1" colspan="1"> -0.5</td></tr></tbody></table><table-wrap-foot><fn id="TFN06"><label>*</label><p>Standard Deviation</p></fn><fn id="TFN07"><label>&#x02020;</label><p>p&#x0003c;0.05</p></fn><fn id="TFN08"><label>&#x02021;</label><p>p&#x0003c;0.001 - paired t-test</p></fn></table-wrap-foot></table-wrap>
</p><p>While the intervention explained 5% of the variability of the proportion of adherence
measure<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup>, the linear regression analysis showed that the Intervention was not
able to explain the variability of the general and specific HRQoL measures.</p></sec><sec><title>Relationship between Adherence and Health Related Quality of Life </title><p>Regarding the correlations between the Morisky scale scores and those of the specific
HRQoL, the absence of correlations was found in the IG, at T<sub>0</sub>. However, at
T<sub>2</sub>, low magnitude negative correlations were observed with the Physical
Functioning (r=-0.29; p=0.04), Emotional Functioning (r=-0.27; p=0.04) and Total
Score (r=-0.29; p=0.04) domains of the MacNew, indicating that the higher the
specific HRQoL, the greater the medication adherence. In the CG, at T<sub>0</sub>, a
significant moderate magnitude negative correlation was found between the Morisky
adherence measure and Emotional Functioning domain of the MacNew (r=-0.31; p=0.02).
At T<sub>2</sub>, no correlations were found between the Morisky adherence scale and
the specific HRQoL measure.</p><p>In the IG, at T<sub>0</sub>, no correlations were found between the Morisky adherence
scale and the generic HRQoL. At T<sub>2</sub> a weak positive correlation was found
between the total score of the Morisky scale and the Emotional Aspects domain
(r=0.27; p=0.04) of the SF-36, contrary to the previously established hypotheses. In
the CG, at T<sub>0</sub>, weak negative correlations were found between the Morisky
scale and the Pain (r=-0.26; p=0.05) and Mental Health (r=-0.29; p=0.03) domains,
indicating that the better generic HRQoL the higher the favorability for adherence.
At T<sub>2</sub> no significant correlations were found for this group.</p><p>In the IG at T<sub>0,</sub> no correlations were found between the proportion of
adherence and the specific HRQoL. At T<sub>2</sub>, significant weak to moderate
correlations were observed between the proportion of adherence and the Social
Functioning domain (r=0.34; p=0.01) and Total Score (r=0.29; p=0.04) of the MacNew,
indicating that the higher the specific HRQoL the better the adherence. However, in
the CG at T<sub>0,</sub> a negative correlation was found between the proportion of
adherence and the Social Aspect domain (r= -0.28; p=0.04) of the MacNew,
contradicting the previously formulated hypotheses. No significant correlations were
found at T<sub>2.</sub>
</p><p>With regard to the relationship between the proportion of adherence and the general
HRQoL measure, in the IG at T<sub>0,</sub> a weak correlation was found with the
General Health Status domain (r=0.26; p=0.05) of the SF-36. At T<sub>2</sub> a
moderate positive correlation was observed between the Emotional Aspects domain
(r=0.30; p=0.02) of the SF-36, confirming the previously established hypotheses.
However, in the CG at T<sub>0</sub>, significant low to moderate negative
correlations were found between the proportion of adherence and the General Health
Status (r= -0.42; p=0.00) and Social Functioning (r=- 0.28; p=0.04) domains of the
SF-36, contrary to the previously established hypotheses. At T<sub>2</sub> a
significant moderate negative correlation was also found between the proportion of
adherence and the General Health Status domain of the SF-36 (r=-0.28; p=0.03).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study aimed to compare the general and specific HRQoL of coronary artery disease
patients allocated in IG and CG after implementing an intervention based on Action
Planning and Coping Planning strategies for medication adherence, as well as to verify
the existence of a relationship between adherence and HRQoL over two months of
monitoring.</p><p>The findings indicate that at T<sub>2</sub>, the IG patients presented a significant
increase in mean scores in all the MacNew domains as well as the Functional Capacity and
Emotional Aspects domains of the SF-36 when compared to the scores obtained at the start
of the study (T<sub>0</sub>). Weak to moderate associations were found between adherence
and the specific measure of HRQoL. However, the findings were not consistent over the
subsequent two months.</p><p>The relationship between adherence and specific HRQoL (MacNew) were found especially in
the IG at the end of the two month monitoring (T<sub>2</sub>), for both measures
employed - proportion of adherence and the Morisky scale. Significant low magnitude
negative correlations were found between the Morisky scale and the Physical Functioning,
Emotional Functioning domains and the Total Score of the MacNew and weak to moderate
correlations between the proportion of adherence and the Social Functioning domain and
Total Score of the MacNew. However, an unexpected correlation in the CG at T<sub>0</sub>
was observed between the proportion of adherence and the Social Functioning domain of
the MacNew. In summary, the greater the favorability of adherence, the better the HRQoL
in all domains and the Total Score of the MacNew.</p><p>In the analysis of the relationship between adherence and general HRQoL (SF-36) the
correlations occurred at both times (T<sub>0</sub> and T<sub>2</sub>) and in both groups
(IG and CG). In the IG the relationship was highlighted between the proportion of
adherence and the General Health Status (at T<sub>0</sub>) and Emotional Aspects (at
T<sub>2</sub>) domains. In the IG, the Morisky measure of adherence did not correlate
with the general HRQoL, except for an unexpected positive correlation with the Emotional
Aspect domain. In the CG negative correlations were found between the Morisky adherence
scale and the Pain and Mental Health domains, while the proportion of adherence
correlated negatively and unexpectedly with the General Health Status (at T<sub>0</sub>
and T<sub>2</sub>) and Social Aspects (at T<sub>0</sub>) domains. These findings suggest
that the relationship between adherence and general HRQoL is less consistent compared to
the results of the specific measure.</p><p>In the present study, although the IG presented better HRQoL in all domains of the
MacNew and in the Functional Capacity and Emotional State domains of the SF-36, the
intervention was not able to explain the variability in HRQoL after two months of
monitoring. One explanation for this finding is the limitation of self-reported measures
in the accurate measurement of adherence, as well as the limited time period for
applying the intervention to change behavior as complex as adherence.</p><p>The weak to moderate magnitude correlations between adherence and HRQoL reported in the
literature and demonstrated in the present study are consistent with the current
recognition that other factors, in addition to the physical and emotional, affect the
HRQoL. The exact mechanism by which medication adherence is associated with HRQoL is
still unknown, with suggestions that HRQoL is part of a complex network of psychosocial
characteristics that influence the patient's ability to cope with the chronicity of the
disease<sup>(5) </sup>.</p><p>Previous findings<sup>(4) </sup>involving type 2 diabetic patients showed that
medication adherence was not associated with the HRQoL domains. However, an association
was observed with the combination of knowledge about the medical prescription and the
attitude toward medication adherence, indicating the need for research into the
determinant psychosocial variables for adherence behavior.</p><p>The absence or weak relationship between adherence and HRQoL were observed in other
studies using self-reported measures<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> as well as those using electronic records of prescriptions<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>,</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup>
<sub>.</sub> Thus, our results may reflect the limitations of different methods used for
measuring medication adherence. Another limitation is the fact that, in the sample
studied, the determinant psychosocial variables for medication adherence that could lead
to the better design of the intervention were unknown - whether motivational and/or
motivational and volitional. Further studies are recommended in order to deepen the
knowledge about the longitudinal relationship between adherence to cardioprotective and
symptom relief medications and HRQoL. Further investigation into the possible mediating
effect of motivational and volitional determinants in medication adherence is suggested.
The elucidation of these relationships will contribute to the design of theory-based
interventions that are most effective in promoting adherence and, consequently, in
improving HRQoL among CAD patients.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The findings indicate that the intervention based on Action Planning and Coping Planning
strategies for medication adherence did not affect the generic and specific measures of
HRQoL in coronary disease outpatients. Regarding the relationship between adherence and
HRQoL, significant, although weak to moderate, correlations were found between the
medication adherence measures used in this study and the HRQoL measures, especially
between medication adherence and the specific measure of HRQoL. Future studies are
recommended in order to elucidate the psychosocial mediatory factors of the relationship
between medication adherence and HRQoL, with a view to outlining nursing interventions
effective in promoting medication adherence and improved HRQoL in patients suffering
from coronary artery disease.</p></sec></body><back><fn-group><fn id="fn01" fn-type="supported-by"><label>1</label><p>Paper extracted from master's thesis "Effect of the action and coping planning in
medication adherence and quality of life of patients with coronary hearty disease",
presented to Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Universidade Estadual de Campinas,
Campinas, SP, Brazil. Supported by Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o
Paulo (FAPESP), Brazil, process # 2009/12783-4 and # 2010/10006-8.</p></fn></fn-group><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Heart Association</collab></person-group><article-title>Heart disease and stroke statistics - 2012 Update: A
report from the American Heart Association</article-title><source>Circulation.</source><year>2012</year><volume>125</volume><fpage>e2</fpage><lpage>e220</lpage><pub-id pub-id-type="pmid">22179539</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>NM</given-names></name></person-group><article-title>Improving medication adherence in chronic cardiovascular
disease</article-title><source>Crit Care Nurse.</source><year>2008</year><volume>28</volume><fpage>54</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">18827087</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>RB</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Degani</surname><given-names>A</given-names></name><name><surname>Kripalani</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name><name><surname>McDonald</surname><given-names>HP</given-names></name></person-group><article-title>Interventions for enhancing medication
adherence</article-title><source>Cochrane Database Syst Rev.</source><day>19</day><month>10</month><year>2005</year><issue>4</issue><fpage>CD000011</fpage><lpage>CD000011</lpage><pub-id pub-id-type="pmid">16235271</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billups</surname><given-names>SJ</given-names></name><name><surname>Malone</surname><given-names>DC</given-names></name><name><surname>Carter</surname><given-names>BL</given-names></name></person-group><article-title>The relationship between drug therapy noncompliance and
patients characteristics, health-related quality of life and health care
costs</article-title><source>Pharmacotherapy.</source><year>2000</year><volume>20</volume><issue>8</issue><fpage>941</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">10939555</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>EW</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Joyce</surname><given-names>CJ</given-names></name><name><surname>Webber</surname><given-names>L</given-names></name><name><surname>Krousel-Wood</surname><given-names>MA</given-names></name></person-group><article-title>Health-related quality of life and antihypertensive
medication adherence among older adults</article-title><source>Age Ageing.</source><year>2010</year><volume>39</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">20513770</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turpin</surname><given-names>RS</given-names></name><name><surname>Simmons</surname><given-names>JB</given-names></name><name><surname>Lew</surname><given-names>JF</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name><name><surname>Dupee</surname><given-names>MA</given-names></name><name><surname>Kavanagh P et</surname><given-names>al</given-names></name></person-group><article-title>Improving treatment regimen adherence in coronary heart
disease by targeting patient types</article-title><source>Dis Manage Health Outcomes</source><year>2004</year><volume>12</volume><issue>6</issue><fpage>377</fpage><lpage>383</lpage></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cot&#x000ea;</surname><given-names>I</given-names></name><name><surname>Farris</surname><given-names>K</given-names></name><name><surname>Feeny</surname><given-names>D</given-names></name></person-group><article-title>Is adherence to drug treatment correlated with
health-related quality of life?</article-title><source>Qual Life Res.</source><year>2003</year><volume>12</volume><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">14516172</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzemer</surname><given-names>WL</given-names></name><name><surname>Corless</surname><given-names>IB</given-names></name><name><surname>Nokes</surname><given-names>KM</given-names></name><name><surname>Turner</surname><given-names>JG</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Powell-Cope</surname><given-names>GM</given-names></name></person-group><article-title>Predictors of self-reported adherence in persons living
with HIV disease</article-title><source>AIDS Patient Care STDS.</source><year>1999</year><volume>13</volume><issue>3</issue><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">10375267</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JC</given-names></name><name><surname>Nichol</surname><given-names>MB</given-names></name><name><surname>Venturini</surname><given-names>F</given-names></name><name><surname>Bailey</surname><given-names>KL</given-names></name><name><surname>McCombs</surname><given-names>JS</given-names></name></person-group><article-title>Factors affecting patient compliance with anti
hyperlipidemic medications in an HMO population</article-title><source>Am J Manag Care.</source><year>1998</year><volume>4</volume><issue>10</issue><fpage>1421</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">10338735</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Manias</surname><given-names>E</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name></person-group><article-title>Interventions to improve medication adherence in people
with multiple conditions: a systematic review</article-title><source>J Adv Nurs.</source><year>2008</year><volume>63</volume><issue>2</issue><fpage>132</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">18537843</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>LB</given-names></name><name><surname>Rodrigues</surname><given-names>RC</given-names></name><name><surname>Ciol</surname><given-names>MA</given-names></name><name><surname>S&#x000e3;o-Jo&#x000e3;o</surname><given-names>TM</given-names></name><name><surname>Corn&#x000e9;lio</surname><given-names>ME</given-names></name><name><surname>Dantas</surname><given-names>RA</given-names></name></person-group><article-title>A randomized controlled trial of the effectiveness of
planning strategies in the adherence to medication for coronary artery
disease</article-title><source>J Adv Nurs.</source><year>2013</year><volume>70</volume><issue>7</issue><fpage>1616</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">24313446</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jannuzzi</surname><given-names>FF</given-names></name></person-group><source xml:lang="pt">Qualidade de vida relacionada &#x000e0; fun&#x000e7;&#x000e3;o visual e ades&#x000e3;o
medicamentosa em idosos com retinopatia diab&#x000e9;tica. Disserta&#x000e7;&#x000e3;o [Mestrado]</source><publisher-loc>Campinas</publisher-loc><publisher-name>Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas da Universidade Estadual de
Campinas</publisher-name><year>2009</year></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>MCS</given-names></name><name><surname>Gallani</surname><given-names>MCBJ</given-names></name></person-group><article-title xml:lang="pt">Adapta&#x000e7;&#x000e3;o transcultural do instrumento de Morisky de
ades&#x000e3;o a medica&#x000e7;&#x000e3;o para pacientes com insufici&#x000ea;ncia card&#x000ed;aca</article-title><source>Rev Soc Cardiol Estado de S&#x000e3;o Paulo.</source><year>2006</year><volume>16</volume><fpage>116</fpage><lpage>116</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciconelli</surname><given-names>RM</given-names></name><name><surname>Ferraz</surname><given-names>MB</given-names></name><name><surname>Santos</surname><given-names>W</given-names></name><name><surname>Mein&#x000e3;o</surname><given-names>I</given-names></name><name><surname>Marina</surname><given-names>RQ</given-names></name></person-group><article-title>Translation to the Portuguese language and general
questionnaire of Quality of Life SF-36 evaluation (Brasil SF-36)</article-title><source>Rev Bras Reumatol.</source><year>1999</year><volume>39</volume><fpage>143</fpage><lpage>150</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benetti</surname><given-names>M</given-names></name><name><surname>Nahas</surname><given-names>MV</given-names></name><name><surname>Barros</surname><given-names>MVG</given-names></name></person-group><article-title>Reproducibility and validity of a Brazilian version of
the MacNew quality of life after myocardial infarction (MacNew QLMI)
questionnaire</article-title><source>Med Sci Sports Exerc.</source><year>2001</year><volume>33</volume><issue>5</issue><fpage>S62</fpage><lpage>S62</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollwitzer</surname><given-names>PM</given-names></name><name><surname>Brandstatter</surname><given-names>V</given-names></name></person-group><article-title>Implementation intentions: Strong effects of simple
plans</article-title><source>American Psychologist</source><year>1999</year><volume>54</volume><issue>7</issue><fpage>493</fpage><lpage>503</lpage></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orbell</surname><given-names>S</given-names></name><name><surname>Sheeran</surname><given-names>P</given-names></name></person-group><article-title>Motivational and volitional processes in action
initiation: A field study of implementation intentions</article-title><source>J Appl Soc Psychol.</source><year>2000</year><volume>30</volume><issue>4</issue><fpage>780</fpage><lpage>797</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>RCM</given-names></name><name><surname>Gallani</surname><given-names>MCBJ</given-names></name><name><surname>Corn&#x000e9;lio</surname><given-names>ME</given-names></name><name><surname>Alexandre</surname><given-names>NMC</given-names></name><name><surname>S&#x000e3;o-Jo&#x000e3;o</surname><given-names>TM</given-names></name></person-group><article-title>The 'Moving Heart Program': an intervention to improve
physical activity among patients with coronary heart disease</article-title><source>Rev. Latino-Am. Enfermagem.</source><year>2013</year><volume>21</volume><issue>spec number</issue><fpage>180</fpage><lpage>189</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura-Cerd&#x000e1;</surname><given-names>JM</given-names></name><name><surname>M&#x000ed;nguez-Gallego</surname><given-names>C</given-names></name><name><surname>Fernandez-Villalba</surname><given-names>EM</given-names></name><name><surname>Al&#x000f3;s-Almi&#x000f1;ana</surname><given-names>M</given-names></name><name><surname>Andr&#x000e9;s-Soler</surname><given-names>J</given-names></name></person-group><article-title xml:lang="pt">Escala simplificada para detectar problemas de
adherencia (ESPA) al tratamiento antirretroviral</article-title><source>Farm Hosp.</source><year>2006</year><volume>30</volume><issue>3</issue><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">16999564</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>RA</given-names></name><name><surname>Kim</surname><given-names>MM</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Tu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>MD</given-names></name></person-group><article-title>Comparison of methods to assess medication adherence and
classify nonadherence</article-title><source>Ann Pharmacother.</source><year>2009</year><volume>43</volume><issue>3</issue><fpage>413</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">19261962</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldridge</surname><given-names>N</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Crowe</surname><given-names>J</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Feeny D et</surname><given-names>al</given-names></name></person-group><article-title>Effects on quality of life with comprehensive
rehabilitation after acute myocardial infarction</article-title><source>Am J Cardiol.</source><year>1991</year><volume>67</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">2024598</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Heller</surname><given-names>RF</given-names></name><name><surname>Knapp</surname><given-names>J</given-names></name></person-group><article-title>An improved questionnaire for assessing quality of life
after acute myocardial infarction</article-title><source>Qual Life Res.</source><year>1996</year><volume>5</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">8901378</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>KM</given-names></name><name><surname>Rodrigues</surname><given-names>RCM</given-names></name><name><surname>Gallani</surname><given-names>MCBJ</given-names></name><name><surname>Alexandre</surname><given-names>NMC</given-names></name><name><surname>Oldridge</surname><given-names>N</given-names></name></person-group><article-title>Psychometric properties of MacNew Heart Disease
Health-related Quality of Life Questionnaire: Brazilian version</article-title><source>J Adv Nurs.</source><year>2009</year><volume>65</volume><issue>5</issue><fpage>1084</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">19291183</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name><collab>IQOLA Project Group</collab></person-group><article-title>The SF-36 health survey: development and use in mental
health research and the IQOLA Project</article-title><source>Int J Mental Health.</source><year>1994</year><volume>23</volume><issue>2</issue><fpage>49</fpage><lpage>73</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ajzen</surname><given-names>I</given-names></name><name><surname>Fishbein</surname><given-names>M</given-names></name></person-group><source>Understanding Attitudes and Predicting Social Behavior</source><publisher-loc>New Jersey</publisher-loc><publisher-name>Prentice-Hall</publisher-name><year>1980</year></element-citation></ref></ref-list></back></article>